Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures

Osteoporosis International

Volumn 21, Issue 12, 2010, Pages 1993-2002

  Rabenda, V ^a   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Compliance; Hip fracture; Nonvertebral fracture; Strontium ranelate

Indexed keywords

CALCIUM; PLACEBO; STRONTIUM RANELATE; VITAMIN D;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; POST HOC ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION;

EID: 78549267137     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1155-z     Document Type: Article

References (48)

1. AD Woolf B Plefger 2003 Burden of major musculoskeletal conditions Bull WHO 81 646 656 14710506
2. SR Cummings LJ Melton III 2002 Epidemiology and outcomes of osteoporotic fractures Lancet 359 1761 1767 10.1016/S0140-6736(02)08657-9 12049882 (Pubitemid 34614532)
3. M Schwenkglenks K Lippuner HJ Hauselmann TD Szucs 2005 A model of osteoporosis impact in Switzerland 2000-2020 Osteoporos Int 16 659 671 10.1007/s00198-004-1743-x 15517190 (Pubitemid 40897464)
4. S Puffer DJ Torgeson D Sykes, et al. 2004 Healthcare costs of women with symptomatic vertebral fractures Bone 35 383 386 10.1016/j.bone.2004.03.035 15268887 (Pubitemid 38953183)
5. E Canalis M Hott P Deloffre Y Tsouderos PJ Marie 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro Bone 18 517 523 1:CAS:528:DyaK28Xkslagu7k%3D 10.1016/8756-3282(96)00080-4 8805991 (Pubitemid 26257871)
6. R Baron Y Tsouderos 2002 In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation Eur J Pharmacol 450 11 17 1:CAS:528:DC%2BD38XmtlKjsb8%3D 10.1016/S0014-2999(02)02040-X 12176103
7. N Takahashi T Sasaki Y Tsouderos T Suda 2003 S 12911-2 inhibits osteoclastic bone resorption in vitro J Bone Miner Res 18 1082 1087 1:CAS:528:DC%2BD3sXkslOhsbk%3D 10.1359/jbmr.2003.18.6.1082 12817762 (Pubitemid 37294946)
8. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector J Cannata A Balogh E-M Lemmel S Pors-Nielsen R Rizzoli HK Genant J-Y Reginster 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468 1:CAS:528: DC%2BD2cXos1Snsw%3D%3D 10.1056/NEJMoa022436 14749454 (Pubitemid 38133766)
9. J-Y Reginster E Seeman MC De Vernejoul S Adami J Compston C Phenekos JP Devogelaer M Diaz Curiel A Sawicki S Goemarere OH Sorensen D Felsenberg PJ Meunier 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 2822 1:CAS:528: DC%2BD2MXkt1Wgt78%3D 10.1210/jc.2004-1774 15728210 (Pubitemid 40686329)
10. JJ Caro KJ Ishak KF Huybrechts, et al. 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008 10.1007/s00198-004-1652-z 15167989 (Pubitemid 40064656)
11. JS McCombs P Thibaud C McLaughlin-Miley, et al. 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 1:CAS:528:DC%2BD2cXltVCiu7g%3D 10.1016/j.maturitas.2004.02.005 15207894 (Pubitemid 38781153)
12. RA Yood S Emani JI Reed, et al. 2003 Compliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 965 968 1:CAS:528: DC%2BD3sXpvVCms74%3D 10.1007/s00198-003-1502-4 14504697 (Pubitemid 40824268)
13. V Rabenda R Mertens V Fabri J Vanoverloop F Sumkay C Vannecke A Deswaef GA Verpooten JY Reginster 2008 Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 811 818 1:CAS:528:DC%2BD1cXltFyjurs%3D 10.1007/s00198-007-0506-x 17999022
14. PD Delmas B Vrijens R Eastell C Roux HA Pols JD Ringe A Grauer D Cahall NB Watts 2007 Improving Measurements of Persistence on Actonel Treatment (IMPACT) investigators effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 1296 1304 1:CAS:528:DC%2BD2sXksVSrsbc%3D 10.1210/jc.2006-1526 17244788 (Pubitemid 46556401)
15. J Finigan PR Bainbridge R Eastell 2001 Adherence to osteoporosis therapies Osteoporos Int 12 S48 S49 P110[abstract]
16. RJ Sebaldt LG Shane B Pham, et al. 2004 Longer term effectiveness outcomes of noncompliance and nonpersitence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care Osteoporos Int 15 Suppl 1 S107 [abstract P391SA]
17. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 10.1016/j.bone.2005.10.022 16330270 (Pubitemid 44498580)
18. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 10.4065/81.8.1013 16901023
19. D Weycker D Macarios J Edelsberg G Oster 2007 Compliance with osteoporosis drug therapy and risk of fracture Osteoporos Int 18 271 277 1:STN:280:DC%2BD2s%2FoslKktg%3D%3D 10.1007/s00198-006-0230-y 17021945 (Pubitemid 46233172)
20. GA Wells A Cranney J Peterson M Boucher B Shea V Robinson D Coyle P Tugwell 2008 Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 1 CD004523 18254053
21. GA Wells A Cranney J Peterson M Boucher B Shea V Robinson D Coyle P Tugwell 2008 Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 1 CD001155 18253985
22. ND Nguyen JA Eisman TV Nguyen 2006 Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials J Bone Miner Res 21 340 349 1:CAS:528:DC%2BD28Xhs1Klsrw%3D 10.1359/JBMR.050903 16526127 (Pubitemid 43265301)
23. S O'Donnell A Cranney GA Wells JD Adachi JY Reginster 2006 Strontium ranelate for preventing and treating postmenopausal osteoporosis Cochrane Database Syst Rev 4 CD005326 17054253
24. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group. Lancet 348 1535 1541 1:CAS:528:DyaK2sXisFCktQ%3D%3D
25. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut 3rd J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) study group JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10.1001/jama.282.14.1344 10527181 (Pubitemid 29483192)
26. J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group Osteoporos Int 11 83 91 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10.1007/s001980050010 10663363 (Pubitemid 30099515)
27. UA Liberman SR Weiss J Broll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs Jr J Dequeker M Favus 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. the Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437 1443 1:CAS:528:DyaK28XkslehtA%3D%3D 10.1056/NEJM199511303332201 7477143
28. AY Ho AW Kung 2005 Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women Ann Pharmacother 39 1428 1433 1:CAS:528:DC%2BD2MXhtVWjtrvL 10.1345/aph.1E580 16076919 (Pubitemid 41197121)
29. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta J Stakkestad CC Gluer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637 645 1:CAS:528: DyaK1MXlvVKqurg%3D 10.1001/jama.282.7.637 10517716 (Pubitemid 29384151)
30. JA Clowes NF Peel R Eastell 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocrinol Metab 89 1117 1123 1:CAS:528:DC%2BD2cXisVWrtbo%3D 10.1210/jc.2003-030501 15001596 (Pubitemid 38368399)
31. G Breart M Audran ML Brandi J Bröll ATN Hamdy FJ Jakob EV McCloskey S Palacios 2009 Good safety and persistence of strontium ranelate in a prospective observational cohort study Osteoporos Int 20 suppl1 S94 (P273) [abstract]
32. JC Lo AR Pressman MA Omar B Ettinger 2006 Persistence with weekly alendronate therapy among postmenopausal women Osteoporos Int 17 922 928 1:CAS:528:DC%2BD28XkvVCnurY%3D 10.1007/s00198-006-0085-2 16609824 (Pubitemid 43781507)
33. DH Solomon J Avorn JN Katz JS Finkelstein M Arnold JM Polinski MA Brookhart 2005 Compliance with osteoporosis medications Arch Intern Med 165 2414 2419 10.1001/archinte.165.20.2414 16287772 (Pubitemid 41640855)
34. MC Chapuy R Pamphile E Paris, et al. 2002 Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study Osteoporos Int 13 257 264 1:CAS:528:DC%2BD38XksVynt7g%3D 10.1007/s001980200023 11991447 (Pubitemid 34408194)
35. MC Chapuy ME Arlot F Duboeuf, et al. 1992 Vitamin D3 and calcium to prevent hip fractures in the elderly women N Engl J Med 327 1637 1642 1:STN:280:DyaK3s%2FmtlSrug%3D%3D 10.1056/NEJM199212033272305 1331788
36. MC Chapuy ME Arlot PD Delmas PJ Meunier 1994 Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women BMJ 308 1081 1082 1:STN:280:DyaK2c3islKnuw%3D%3D 8173430
37. B Dawson-Hughes SS Harris EA Krall GE Dallal 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 337 670 376 1:CAS:528:DyaK2sXmt1Wqtbk%3D 10.1056/ NEJM199709043371003 9278463 (Pubitemid 27375473)
38. ER Larsen L Mosekilde A Foldspang 2004 Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study J Bone Miner Res 19 370 378 1:CAS:528:DC%2BD2cXisFCrsL0%3D 10.1359/JBMR.0301240 15040824 (Pubitemid 38787391)
39. J Porthouse S Cockayne C King, et al. 2005 Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care BMJ 330 1003 1008 1:CAS:528:DC%2BD2MXkslKlu78%3D 10.1136/bmj.330.7498.1003 15860827
40. RD Jackson AZ LaCroix M Gass, et al. 2006 Calcium plus vitamin D supplementation and the risk of fractures N Engl J Med 354 669 683 1:CAS:528:DC%2BD28XhsVWksr0%3D 10.1056/NEJMoa055218 16481635 (Pubitemid 43247138)
41. The RECORD Trial Group 2005 Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial Lancet 365 1621 1628 10.1016/S0140-6736(05)63013-9 (Pubitemid 40693411)
42. P Lips WC Graafmans ME Ooms PD Bezemer LM Bouter 1996 Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial Ann Intern Med 124 400 406 1:STN:280:DyaK287ltF2nsQ%3D%3D 8554248
43. DP Trivedi R Doll KT Khaw 2003 Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial BMJ 326 469 474 1:CAS:528:DC%2BD3sXisFart7Y%3D 10.1136/bmj.326.7387.469 12609940
44. SH Simpson DT Eurich SR Majumdar RS Padwal RT Tsuyuki J Varney JA Johnson 2006 A meta-analysis of the association between adherence to drug therapy and mortality BMJ 333 15 10.1136/bmj.38875.675486.55 16790458
45. R Sikka F Xia RE Aubert 2005 Estimating medication persistency using administrative claims data Am J Manag Care 11 449 457 16044982
46. T Pullar S Kumar H Tindall M Feely 1989 Time to stop counting the tablets? Clin Pharmacol Ther 46 163 168 1:STN:280:DyaL1MzjslarsA%3D%3D 10.1038/clpt.1989.121 2758726
47. P Rudd RL Byyny V Zachary ME LoVerde WD Mitchell C Titus G Marshall 1988 Pill count measures of compliance in a drug trial: variability and suitability Am J Hypertens 1 3 Pt 1 309 312 1:STN:280:DyaL1c3mvFaisQ%3D%3D 3291897
48. M Stewart 1987 The validity of an interview to assess a patient's drug taking Am J Prev Med 3 95 100 1:STN:280:DyaL1c3ltFOnug%3D%3D 3330658